Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data

In the original publication, part Fig. 3b and c were interchanged. The correct versions are given below.

متن کامل

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data

INTRODUCTION We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA. METHODS Assessments included an evaluation of the Psoriasis Area and Severity Index ...

متن کامل

Certolizumab pegol for the treatment of psoriatic arthritis.

Certolizumab pegol (CZP) is a TNF-α inhibitor approved for the treatment of psoriatic arthritis in 38 countries, including many European countries and the USA. It is a pegylated humanized anti-TNF-α antigen-binding fragment, administered subcutaneously. As other TNF-α antibodies, CZP binds to and neutralizes both soluble and membrane TNF-α. In contrast to whole antibodies and etanercept, CZP do...

متن کامل

Certolizumab pegol for the treatment of rheumatoid arthritis.

INTRODUCTION Improved understanding of the pathogenesis of rheumatoid arthritis (RA), and subsequent development of targeted therapies, have greatly advanced the management of this chronic inflammatory disease. The aim of treatment is a state of clinical remission. Certolizumab pegol (CZP) is a novel pegylated TNF alpha inhibitor (TNFi) therapy and is the focus of this review. AREAS COVERED C...

متن کامل

Depression and quality of life in psoriasis and psoriatic arthritis patients

ackground: Psoriasis is a chronic hyperproliferative disease of the skin, scalp, nails, and joints that affects 2% of the general population. One of the extracutaneous manifestations of psoriasis is psoriatic arthritis which occurs in 25–34% of the psoriasis cases. This type of inflammatory arthritis is characterized by pain, swelling, and tenderness around the joints, and may adversely a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Dermatology and Therapy

سال: 2017

ISSN: 2193-8210,2190-9172

DOI: 10.1007/s13555-017-0208-z